A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.

被引：7
|
作者：
Bekaii-Saab, Tanios S.
Mikhail, Sameh
Langleben, Adrian
Becerra, Carlos
Jonker, Derek J.
Asmis, Timothy R.
Cote, Gregory Michael
Wu, Christina Sing-Ying
Kwak, Eunice Lee
Spira, Alexander I.
Braiteh, Fadi S.
Richey, Stephen Lane
Hume, Stephanie
Hitron, Matthew
Li, Chiang
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Solove Res Inst, Columbus, OH 43210 USA
[2] St Marys Hosp, Westmount, PQ, Canada
[3] Texas Oncol, Baylor Sammons Canc Ctr, Dallas, TX USA
[4] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Richard J Solove Res Inst, Columbus, OH 43210 USA
[7] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[8] Virginia Canc Specialists Res Inst, US Oncol Res, Fairfax, VA USA
[9] McKesson Specialty Hlth, US Oncol Network, The Woodlands, TX USA
[10] Texas Oncol, US Oncol Network, McKesson Specialty Hlth, Ft Worth, TX USA
[11] Boston Biomed Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.196
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Becerra, Carlos
    Stephenson, Joe
    Jonker, Derek J.
    Cohn, Allen Lee
    Asmis, Timothy R.
    Bekaii-Saab, Tanios S.
    Conkling, Paul R.
    Garbo, Lawrence E.
    Lenz, Heinz-Josef
    Richards, Donald A.
    Spira, Alexander I.
    Mikhail, Sameh
    Goodwin, Rachel Anne
    Yoon, Harry H.
    Hume, Stephanie
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A Phase Ib/II Study of Cancer Sternness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
    Becerra, Carlos
    Braiteh, Fadi S.
    Spira, Alexander I.
    Langleben, Adrian
    Panasci, Lawrence C.
    Vukelja, Svetislava J.
    Hinshaw, Ioana M.
    Goodwin, Rachel Anne
    Panella, Timothy J.
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC)
    Hubbard, Joleen Marie
    Jonker, Derek J.
    O'Neil, Bert H.
    Halfdanarson, Thorvardur Ragnar
    Grothey, Axel
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
    Becerra, Carlos
    Spira, Alexander I.
    Conkling, Paul R.
    Richey, Stephen Lane
    Hanna, Wahid Tewfik
    Cote, Gregory Michael
    Heist, Rebecca Suk
    Langleben, Adrian
    Laurie, Scott Andrew
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.
    Garcia, Agustin A.
    Hays, John L.
    Cote, Gregory Michael
    Becerra, Carlos
    Langleben, Adrian
    Lau, Susie K.
    Roman, Lynda D.
    McCormick, Colleen Catherine
    Richards, Donald A.
    Braiteh, Fadi S.
    Yimer, Habte Aragaw
    Richey, Stephen Lane
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies
    Hitron, Matthew
    Stephenson, Joe
    Chi, Kim N.
    Edenfield, William Jeffery
    Leggett, David
    Li, Youzhi
    Li, Wei
    Gada, Keyur
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).
    Mason, Warren P.
    de Robles, Paula
    Borodyansky, Laura
    Hitron, Matthew
    Ortuzar, Waldo Feliu
    Khan, Waheed
    Xu, Bo
    Li, Wei
    Li, Youzhi
    Li, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] A phase I study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer.
    Shitara, Kohei
    Kuboki, Yasutoshi
    Nakamura, Yoshiaki
    Doi, Ayako
    Harada, Kazuaki
    Kawazoe, Akihito
    Doi, Toshihiko
    Yoshino, Takayuki
    Yodo, Yasuhide
    Yoshikawa, Reigetsu
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).
    El-Rayes, Bassel F.
    Richards, Donald A.
    Cohn, Allen Lee
    Richey, Stephen Lane
    Feinstein, Trevor
    Kundranda, Madappa N.
    El-Khoueiry, Anthony B.
    Melear, Jason M.
    Braiteh, Fadi S.
    Hitron, Matthew
    Ortuzar, Waldo Feliu
    Khan, Waheed
    Xu, Bo
    Li, Wei
    Li, Youzhi
    Li, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Phase Ib/II study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
    Acoba, Jared David
    Rock, Amy
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345